On Point: Biologics Drive Growth in Pre-Filled Syringes

With an aging population, the resultant increase in prevalence of chronic diseases, and more demand from patients for dosing convenience, the biopharma industry has seen an exponential increase in adoption of biological therapies delivered in prefilled syringes. The overall prefilled syringes market is forecasted to be worth nearly $10 billion by the year 2025, according to market research (1), driven in part by the rise in use of biological drugs. This article discusses the challenges, safety considerations, and emerging trends in the field of pre-filled syringes for biologics.

Read this article in Pharmaceutical Technology Biologics and Sterile Drug Manufacturing May 2020 eBook.

Article Details

Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing, May 2020
May 2020
Pages: 20–23

Citation

When referring to this article, please cite it as F. Thomas, "On Point: Biologics Drive Growth in Pre-Filled Syringes," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2020).